SequelSEC

IDEAYA Biosciences, Inc. IDYA

Pharmaceutical Preparations · CIK 0001676725 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$218.71M
Fiscal year ended 2025-12-31
Operating income
-$159.31M
Fiscal year ended 2025-12-31
Free cash flow
-$73.47M
Fiscal year ended 2025-12-31

IDEAYA Biosciences, Inc. (IDYA) reported revenue of $218.71M and net income of -$113.70M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from IDEAYA Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

IDEAYA Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$218.71M$7.00M$23.38M$50.93M$27.94M$19.54M$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$159.31M-$326.98M-$134.43M-$62.50M-$50.27M-$35.34M-$44.27M
Net income-$113.70M-$274.48M-$112.96M-$58.66M-$49.76M-$34.50M-$41.98M
Research & development$314.70M$294.67M$129.51M$89.54M$58.16M$39.70M$34.32M
Weighted-average diluted sharesshares 88.49Mshares 81.68Mshares 57.52Mshares 41.44Mshares 35.25Mshares 24.72MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0
Diluted EPS$-1.28$-3.36$-1.96$-1.42$-1.41$-1.40Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$63.32M$39.30M$28.31M$23.90M$20.05M$15.18M$9.95M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

IDEAYA Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$112.82M$84.38M$157.02M$68.63M$92.05M$72.04M$34.07M
Total assets$1.11B$1.12B$649.32M$387.97M$381.35M$298.27M$113.00M
Current assets$666.73M$689.71M$532.63M$370.45M$251.00M$288.60M$101.65M
Total liabilities$86.39M$64.94M$28.23M$38.51M$79.83M$100.00M$12.60M
Current liabilities$58.82M$46.07M$27.10M$31.72M$45.16M$38.64M$6.94M
Total equity incl. NCI$1.02B$1.06B$621.09M$349.46M$301.51M$198.27M$100.40M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$3.00K$18.00K$211.00K$1.10M$1.88MUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$17.58M$15.42M$6.60M$4.28M$2.10M$953.00K$709.00K

Cash flow

IDEAYA Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$71.10M-$247.58M-$115.22M-$87.18M-$55.78M$55.46M-$39.31M
Capital expenditures$2.37M$3.86M$2.37M$3.44M$2.64M$493.00K$1.35M
Investing cash flow$69.98M-$502.56M-$158.46M-$33.40M-$69.67M-$146.24M$2.26M
Financing cash flow$29.78M$677.55M$362.72M$97.16M$145.45M$128.75M$50.61M
Net change in cash$28.66M-$72.59M$89.04M-$23.41M$20.01M$37.97M$13.56M
Stock-based compensation$46.12M$34.75M$18.49M$11.63M$8.24M$3.61M$2.17M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$2.70M$2.39M$2.48M$2.10M$1.72M$1.38M$1.40M

Derived

IDEAYA Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$73.47M-$251.44M-$117.59M-$90.62M-$58.42M$54.97M-$40.67M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-72.8%-4671.1%-574.9%-122.7%-179.9%-180.9%Unavailable
FCF margin-33.6%-3592.0%-502.9%-177.9%-209.1%281.3%Unavailable
SBC / revenue21.1%496.4%79.1%22.8%29.5%18.5%Unavailable
Current ratio11.34x14.97x19.65x11.68x5.56x7.47x14.65x
Revenue YoY growth3024.4%-70.1%-54.1%82.3%43.0%UnavailableUnavailable
Net margin-52.0%-3921.1%-483.0%-115.2%-178.1%-176.6%Unavailable
R&D / revenue143.9%4209.6%553.8%175.8%208.1%203.2%Unavailable
CapEx / revenue1.1%55.1%10.1%6.8%9.5%2.5%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IDYA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.